Search

Displaying results 461 - 470 of 4339 in total
  1. Drug

    Clofarabine

    go.drugbank.com/drugs/DB00631
    ApprovedInvestigational

    It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand.

    Products: CLOFAZIC® 20MG/20ML
  2. Drug

    Berahyaluronidase alfa

    go.drugbank.com/drugs/DB22790
    ApprovedInvestigational

    This combination was approved by the US FDA in September 2025 and is indicated for various solid tumors in adults and pediatric patients 12 years and older, offering a subcutaneous option for indications

  3. Drug

    Oxethazaine

    go.drugbank.com/drugs/DB12532
    ApprovedWithdrawn

    [L1113] It is also in the list of approved derivatives of herbal products by the EMA.[L2816] … [A33104] Oxetacaine is approved by Health Canada since 1995 for its use as an antacid combination in over-the-counter preparations.

  4. Drug

    Pibrentasvir

    go.drugbank.com/drugs/DB13878
    ApprovedInvestigational

    Mavyret is also indicated for HCV genotype 1-infected patients who have been previously treated with regimens either containing an NS5A inhibitor or an NS3/4A protease inhibitor, but not both [L940]. … FDA approved an expanded indication for Mavyret, making it the first and only direct-acting antiviral therapy approved for the treatment of both acute and chronic HCV in patients aged three years and older

    Mixtures: MAVIRET FILM-COATED TABLET 100MG/40MG, MAVIRET (GLECAPREVIR 100MG/ PIBRENTASVIR 40MG) FILM COATED TABLETS
  5. Drug

    Odevixibat

    go.drugbank.com/drugs/DB16261
    ApprovedInvestigational

    Odevixibat, or A4250, is an ileal sodium/bile acid cotransporter inhibitor indicated for the treatment of pruritus in patients older than 3 months, with progressive familial intrahepatic cholestasis (PFIC

  6. Drug

    Cilastatin

    go.drugbank.com/drugs/DB01597
    ApprovedInvestigational

    The first combination product containing both drugs was approved by the FDA in November of 1985 under the trade name Primaxin, marketed by Merck & Co. … Since the antibiotic, [imipenem], is one such antibiotic that is hydrolyzed by dehydropeptidase, cilastatin is used in combination with imipenem to prevent its metabolism.

  7. Drug

    Levoleucovorin

    go.drugbank.com/drugs/DB11596
    ApprovedInvestigational

    However, in order to function in this role, it must first be reduced by the enzyme dihydrofolate reductase (DHFR) into the cofactors dihydrofolate (DHF) and tetrahydrofolate (THF). … Folic acid is an essential B vitamin required by the body for the synthesis of purines, pyrimidines, and methionine before incorporation into DNA or protein.

  8. Drug

    Timolol

    go.drugbank.com/drugs/DB00373
    ApprovedInvestigational

    [L6727] Timolol was first approved by the FDA in 1978. … [L6724] This drug is marketed by several manufacturers [L6736] and is an effective agent for the management of conditions such as open-angle glaucoma and hypertension.

    Mixtures: AZARGA 10MG/ML+5MG/ML, COSOPT 20MG/ML+5MG/MLProducts: Blocadren Tab 10mg, Blocadren Tab 20mg
  9. Drug

    Peanut oil

    go.drugbank.com/drugs/DB13964
    ApprovedWithdrawn

    The kernels are consumed roasted but a large percentage is used for the production of vegetable oil.

  10. Drug

    Peramivir

    go.drugbank.com/drugs/DB06614
    ApprovedInvestigational

    The injectable intravenous formulation of peramivir was approved by the FDA in September 2017 for the treatment of acute uncomplicated influenza to pediatric patients 2 years and older who have been symptomatic … Peramivir is an antiviral agent developed by Biocryst Pharmaceuticals to treat influenza A/B.